In an article featured in Business Wire, Synnovation Therapeutics announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation, along with its portfolio of pan-mutant selective PI3Kα inhibitor programs. The agreement includes total cash consideration of up to $3 billion, consisting of $2 billion upfront and up to $1 billion in milestone payments.

The acquisition centers on SNV4818, a Phase 1/2 clinical-stage therapy being evaluated for HR+/HER2- metastatic breast cancer and other solid tumors. The transaction is expected to strengthen Novartis’ oncology pipeline while accelerating the development of targeted treatments for patients with PI3Kα mutation-driven cancers.

This milestone reflects the strength of Synnovation’s scientific innovation and highlights the growing impact of breakthrough therapies emerging from the life sciences ecosystem.

Read the full article: https://www.businesswire.com/news/home/20260319220518/en/Novartis-to-Acquire-Synnovation-Therapeutics-Pan-Mutant-Selective-PI3K-Inhibitor-Program